Research programme: beta 3 adrenoreceptor agonists - sanofi-aventisAlternative Names: SAR-150640
Latest Information Update: 18 Mar 2009
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Mechanism of Action Beta 3 adrenergic receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Preterm labour